middle.news
Actinogen Raises $16.8M to Fuel Pivotal Alzheimer’s Trial and 2026 Growth
9:52am on Friday 27th of February, 2026 AEDT
•
Biotechnology
Read Story
Actinogen Raises $16.8M to Fuel Pivotal Alzheimer’s Trial and 2026 Growth
9:52am on Friday 27th of February, 2026 AEDT
Key Points
Total $16.8 million raised including $4.8 million via share purchase plan
Proforma cash balance of $29.5 million as of December 2025
Funding supports XanaMIA Phase 2b/3 Alzheimer’s trial completion by November 2026
CEO and directors committed to further share subscriptions pending shareholder approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACTINOGEN MEDICAL (ASX:ACW)
OPEN ARTICLE